Relative role of methylator and tumor suppressor pathways in ulcerative colitis-associated colon cancer

Inflammatory Bowel Diseases

Volumn 17, Issue 9, 2011, Pages 1966-1970

  Sanchez, Julian A ^a   Dejulius, Kathryn L ^a   Bronner, Mary ^a   Church, James M ^a   Kalady, Matthew F ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

CIMP; p53; ulcerative colitis

Indexed keywords

B RAF KINASE; K RAS PROTEIN; PROTEIN MLH1; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER INHIBITION; CANCER LOCALIZATION; CANCER STAGING; CANCER TISSUE; CARCINOGENESIS; CODON; COLORECTAL CARCINOMA; CONTROLLED STUDY; CPG ISLAND; CPG ISLAND METHYLATOR PHENOTYPE; DEMOGRAPHY; DNA METHYLATION; EXON; FEMALE; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; TUMOR SUPPRESSOR GENE; ULCERATIVE COLITIS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; COLON; COLORECTAL NEOPLASMS; DNA; DNA METHYLATION; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; RECTUM; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 80755173982     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21526     Document Type: Article

References (35)

1. Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007; 133: 1099-1105; quiz 1340-1341. (Pubitemid 47494461)
2. Eaden JA, Abrams KR, Mayberry JF., The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001; 48: 526-535. (Pubitemid 32234798)
3. Issa JP, Ahuja N, Toyota M, et al. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res. 2001; 61: 3573-3577. (Pubitemid 32694963)
4. Maia L, Dinis J, Cravo M, et al. Who takes the lead in the development of ulcerative colitis-associated colorectal cancers: mutator, suppressor, or methylator pathway? Cancer Genet Cytogenet. 2005; 162: 68-73. (Pubitemid 41278473)
5. Aust DE, Terdiman JP, Willenbucher RF, et al. The APC/beta-catenin pathway in ulcerative colitis-related colorectal carcinomas: a mutational analysis. Cancer. 2002; 94: 1421-1427. (Pubitemid 34212635)
6. Aust DE, Terdiman JP, Willenbucher RF, et al. Altered distribution of beta-catenin, and its binding proteins E-cadherin and APC, in ulcerative colitis-related colorectal cancers. Mod Pathol. 2001; 14: 29-39. (Pubitemid 32098808)
7. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988; 319: 525-532.
8. Lengauer C, Kinzler KW, Vogelstein B., Genetic instability in colorectal cancers. Nature. 1997; 386: 623-627. (Pubitemid 27175430)
9. Thibodeau SN, Bren G, Schaid D., Microsatellite instability in cancer of the proximal colon. Science. 1993; 260: 816-819. (Pubitemid 23167612)
10. Thibodeau SN, French AJ, Roche PC, et al. Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res. 1996; 56: 4836-4840. (Pubitemid 26374414)
11. Cunningham JM, Christensen ER, Tester DJ, et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res. 1998; 58: 3455-3460. (Pubitemid 28371090)
12. Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A. 1998; 95: 6870-6875. (Pubitemid 28278073)
13. Toyota M, Ho C, Ahuja N, et al. Identification of differentially methylated sequences in colorectal cancer by methylated CpG island amplification. Cancer Res. 1999; 59: 2307-2312. (Pubitemid 29242273)
14. Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A. 1999; 96: 8681-8686. (Pubitemid 29354851)
15. Kaneko Y, Sakurai S, Hironaka M, et al. Distinct methylated profiles in Helicobacter pylori dependent and independent gastric MALT lymphomas. Gut. 2003; 52: 641-646. (Pubitemid 36528863)
16. Shen L, Ahuja N, Shen Y, et al. DNA methylation and environmental exposures in human hepatocellular carcinoma. J Natl Cancer Inst. 2002; 94: 755-761. (Pubitemid 34567960)
17. Zhang C, Li Z, Cheng Y, et al. CpG island methylator phenotype association with elevated serum alpha-fetoprotein level in hepatocellular carcinoma. Clin Cancer Res. 2007; 13: 944-952. (Pubitemid 46340371)
18. Eads CA, Lord RV, Kurumboor SK, et al. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res. 2000; 60: 5021-5026.
19. Kalady MF, Sanchez JA, Manilich E, et al. Divergent oncogenic changes influence survival differences between colon and rectal adenocarcinomas. Dis Colon Rectum. 2009; 52: 1039-1045.
20. Eads CA, Danenberg KD, Kawakami K, et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 2000; 28: E32.
21. Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. [see comment]. Nat Genet. 2006; 38: 787-793. (Pubitemid 43980599)
22. Sanchez JA, Krumroy L, Plummer S, et al. Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer. Br J Surg. 2009; 96: 1196-1204.
23. Trinh BN, Long TI, Laird PW., DNA methylation analysis by MethyLight technology. Methods (Duluth). 2001; 25: 456-462. (Pubitemid 34164018)
24. Patocs A, Zhang L, Xu Y, et al. Breast-cancer stromal cells with TP53 mutations and nodal metastases. N Engl J Med. 2007; 357: 2543-2551. (Pubitemid 350294221)
25. Petitjean A, Mathe E, Kato S, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat. 2007; 28: 622-629. (Pubitemid 46744292)
26. Niv Y., Microsatellite instability and MLH1 promoter hypermethylation in colorectal cancer. World J Gastroenterol. 2007; 13: 1767-1769. (Pubitemid 46706008)
27. Ogino S, Goel A., Molecular classification and correlates in colorectal cancer. J Mol Diagn. 2008; 10: 13-27. (Pubitemid 351184831)
28. Konishi K, Shen L, Wang S, et al. Rare CpG island methylator phenotype in ulcerative colitis-associated neoplasias. Gastroenterology. 2007; 132: 1254-1260. (Pubitemid 46627571)
29. Lee S, Cho NY, Yoo EJ, et al. CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels. Arch Pathol Lab Med. 2008; 132: 1657-1665.
30. Jass JR., Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology. 2007; 50: 113-130. (Pubitemid 44953403)
31. Fujii S, Fujimori T, Chiba T., Usefulness of analysis of p53 alteration and observation of surface microstructure for diagnosis of ulcerative colitis-associated colorectal neoplasia. J Exp Clin Cancer Res. 2003; 22: 107-115. (Pubitemid 36396665)
32. Marx A, Wandrey T, Simon P, et al. Combined alpha-methylacyl coenzyme A racemase/p53 analysis to identify dysplasia in inflammatory bowel disease. Hum Pathol. 2009; 40: 166-173.
33. Willenbucher RF, Zelman SJ, Ferrell LD, et al. Chromosomal alterations in ulcerative colitis-related neoplastic progression. Gastroenterology. 1997; 113: 791-801. (Pubitemid 27381138)
34. Yoshida T, Haga S, Numata Y, et al. Disruption of the p53-p53r2 DNA repair system in ulcerative colitis contributes to colon tumorigenesis. Int J Cancer. 2006; 118: 1395-1403.
35. Zambetti GP., The p53 mutation "gradient effect" and its clinical implications. J Cell Physiol. 2007; 213: 370-373. (Pubitemid 47509715)